

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:I13V98%  
cov=66,821 • K14R93%  
cov=69,541 • M36I93%  
cov=67,965 • R41K99%  
cov=66,932 • L63Q94%  
cov=21,568 • **I64ISV**91%  
cov=21,584Y: 99%, S: 24%, L: 15% • H69HK85%  
cov=21,100Y: 85%, K: 10%

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:V35T98%  
cov=9,430 • T39TA7: 60%, A: 26%  
cov=9,373 • E40D96%  
cov=9,339 • S48ST5: 73%, T: 26%  
cov=9,131 • K49KR8: 64%, K: 35%  
cov=9,127 • V60I98%  
cov=9,282 • **L100LS**1: 24%, S: 14%  
cov=9,198 • D121H92%  
cov=8,779 • K122E98%  
cov=8,786 • I135T94%  
cov=9,393 • I142V91%  
cov=9,577 • K173S93%  
cov=11,113 • Q174K94%  
cov=11,120 • D177E98%  
cov=11,489 • T200I91%  
cov=11,331 • Q207E90%  
cov=9,229 • R211K91%  
cov=9,326 • V245K90%  
cov=10,136 • E248D89%  
cov=10,702 • D250E94%  
cov=10,668 • A272P94%  
cov=11,396 • K277R96%  
cov=40,348 • L282C97%  
cov=42,186 • P294T97%  
cov=55,296 • V317A97%  
cov=56,211 • G335D98%  
cov=4,472 • P345Q98%  
cov=4,397 • F346Y99%  
cov=4,396 • R356K97%  
cov=3,894 • M357L99%  
cov=3,885 • A376S98%  
cov=2,903 • T377Q98%  
cov=2,902

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
emtricitabine (FTC)	Susceptible	etravirine (ETR)	Susceptible
lamivudine (3TC)	Susceptible	nevirapine (NVP)	Susceptible
tenofovir (TDF)	Susceptible	rilpivirine (RPV)	Susceptible

RT comments

Other

- L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it confers high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR and DOR. L100V is a rare mutations that likely has effects similar to L100I. **L100S** is a highly unusual mutation at this position.

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.